The Qs were focused over Eylea/Dupi market dynamic (Eylea PD expansion, CMS part B effects, Dupi-asthma penetration/AD-expansion,..answered with confidence and with common sense....), while on pipeline front Qs were on IO, rule of CD3 and new bispecific platform (CD28). While CD3 and CD28 are relative new (uncertain, and Sanofi bailed out leaving REGN with "holding the bag"....did they already forgot Eylea (aflibercept) arrangement and failure on their part????..), I think that Sanofi priorities are not on IO/IO. They fear BMS/MRK have significant lead and investment may over-burn potential return. Contrary, REGN feels opposite...time will tell who is right.
Anyway, I would suggest Conference present. and Q&A parts, make own notes on Qs and project where they stand.
Their burn rate will increase , 19/20, profit will shrink, but few years from now (IF anyone have patience to hold that long) pay-off may be there??? I surely hope it will, but...who hold "crystal-boll"????
Cheers! |
